NKGen Biotech, Inc.

NKGen Biotech is a clinical-stage biotechnology company developing and commercializing natural killer (NK) cell therapies using its proprietary SNK platform. Its autologous, allogeneic, and CAR-NK candidates are intended to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, as well as cancers. The company’s platform uses activated NK cells, which it aims to bring to patients through clinical development and eventual commercialization.